BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38708161)

  • 1. Prognostic Factors and Outcomes of Early-Stage Hodgkin's Lymphoma: Multi-Institutional Data From South India.
    Singuluri LS; Jayachandran PK; Goenka L; Shenoy PK; Rathnam KK; Seshachalam A; Mehra N; Kumar MR; Suseela MM; Raghavan V; Nair CK; Dubashi B; Dhanushkodi M; Ganesan P
    Indian J Hematol Blood Transfus; 2024 Apr; 40(2):237-245. PubMed ID: 38708161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.
    von Tresckow B; Kreissl S; Goergen H; Bröckelmann PJ; Pabst T; Fridrik M; Rummel M; Jung W; Thiemer J; Sasse S; Bürkle C; Baues C; Diehl V; Engert A; Borchmann P;
    Lancet Haematol; 2018 Oct; 5(10):e462-e473. PubMed ID: 30290903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.
    Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Wells WA; Winter JN; Horning SJ; Dar AR; Shustik C; Stewart DA; Crump M; Djurfeldt MS; Chen BE; Shepherd LE; ;
    N Engl J Med; 2012 Feb; 366(5):399-408. PubMed ID: 22149921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors of Hodgkin's lymphoma and their impact on response to chemotherapy and survival.
    Abdel Hamid TM; El Zawahry HM; Khattab NA; Mowafy TM; Awaad MM; Ali El-Din NH; Mokhtar NM
    J Egypt Natl Canc Inst; 2005 Mar; 17(1):9-14. PubMed ID: 16353077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
    Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N
    J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of clinical features and treatment outcomes of children with Hodgkin's Lymphoma treated with different chemotherapy protocols at a tertiary care center in Pakistan.
    Mehreen A; Wali RM; Sindhu II; Asad M; Ria S
    J Pak Med Assoc; 2019 Sep; 69(9):1266-1272. PubMed ID: 31511710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure.
    Liao Z; Ha CS; Vlachaki MT; Hagemeister F; Cabanillas F; Hess M; Tucker S; Cox JD
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):971-7. PubMed ID: 11429225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma.
    Ganesan P; Rajendranath R; Kannan K; Radhakrishnan V; Ganesan TS; Udupa K; Lakshmipathy KM; Mahajan V; Sundersingh S; Rajaraman S; Krishnakumar R; Sagar TG
    Ann Oncol; 2015 Jun; 26(6):1170-1174. PubMed ID: 25701453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment results in advanced stage Hodgkin's lymphoma: a retrospective study.
    Jain H; Sengar M; Nair R; Menon H; Laskar S; Shet T; Gujral S; Sridhar E
    J Postgrad Med; 2015; 61(2):88-91. PubMed ID: 25766339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
    Laskar S; Gupta T; Vimal S; Muckaden MA; Saikia TK; Pai SK; Naresh KN; Dinshaw KA
    J Clin Oncol; 2004 Jan; 22(1):62-8. PubMed ID: 14657226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
    Franklin J; Eichenauer DA; Becker I; Monsef I; Engert A
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD008814. PubMed ID: 28901021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
    Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).
    Johnson PW; Radford JA; Cullen MH; Sydes MR; Walewski J; Jack AS; MacLennan KA; Stenning SP; Clawson S; Smith P; Ryder D; Hancock BW;
    J Clin Oncol; 2005 Dec; 23(36):9208-18. PubMed ID: 16314615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Outcomes of Hodgkin Lymphoma: A Multi-Centric Registry From India.
    Bhurani D; Nair R; Rajappa S; Rao SA; Sridharan N; Boya RR; Raman GS; Menon H; Seshachalam A; Nimmagadda R
    Front Oncol; 2021; 11():799948. PubMed ID: 35223455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Utility of the IPS 3 Score for Predicting Outcomes in Advanced Hodgkin Lymphoma.
    Ganesan P; Dhanushkodi M; Ganesan TS; Radhakrishnan V; Kannan K; Sundersingh S; Sagar TG
    Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):116-122. PubMed ID: 30579722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
    Dieckmann K; Pötter R; Hofmann J; Heinzl H; Wagner W; Schellong G;
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):644-52. PubMed ID: 12788169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.
    Skoetz N; Trelle S; Rancea M; Haverkamp H; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2013 Sep; 14(10):943-52. PubMed ID: 23948348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma.
    Song MK; Chung JS; Lee JJ; Jeong SY; Lee SM; Hong JS; Chong A; Moon JH; Kim JH; Lee SM; Kim SJ; Shin HJ
    Cancer Sci; 2013 Dec; 104(12):1656-61. PubMed ID: 24033666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.